Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Springer

Showing results (231-240 of 280) with videos related to

Pageof 28
Sort By:
American Journal of Respiratory and Critical Care Medicine|April 24, 2001
NK1 receptor stimulation causes contraction and inositol phosphate increase in medium-size human isolated bronchiS Amadesi, J Moreau, M Tognetto, et al.
Journal of Medicinal Chemistry|January 6, 2006
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar leadIon Niculescu-Duvaz, Esteban Roman, Steven R Whittaker, et al.
Journal of Medicinal Chemistry|May 14, 2008
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffoldIon Niculescu-Duvaz, Esteban Roman, Steven R Whittaker, et al.
Disease Markers|May 1, 1991
Antibody directed enzyme prodrug therapy (ADEPT): a three phase systemS K Sharma, K D Bagshawe, C J Springer, et al.
Cell Biophysics|January 1, 1993
Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrugD C Blakey, B E Valcaccia, S East, et al.
Vaccine|February 14, 2016
Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulationMichael J Springer, Yawei Ni, Isaac Finger-Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinomaM P Napier, S K Sharma, C J Springer, et al.
Bioorganic & Medicinal Chemistry|February 5, 2013
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituentsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.
British Journal of Cancer|May 29, 2003
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugsR A Spooner, F Friedlos, K Maycroft, et al.
Oncogene|June 23, 2004
B-RAF is a therapeutic target in melanomaMaria Karasarides, Antonio Chiloeches, Robert Hayward, et al.
Pageof 28

Showing results (231-240 of 280) with videos related to

Sort By:
Pageof 28
American Journal of Respiratory and Critical Care Medicine|April 24, 2001
NK1 receptor stimulation causes contraction and inositol phosphate increase in medium-size human isolated bronchiS Amadesi, J Moreau, M Tognetto, et al.
Journal of Medicinal Chemistry|January 6, 2006
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar leadIon Niculescu-Duvaz, Esteban Roman, Steven R Whittaker, et al.
Journal of Medicinal Chemistry|May 14, 2008
Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffoldIon Niculescu-Duvaz, Esteban Roman, Steven R Whittaker, et al.
Disease Markers|May 1, 1991
Antibody directed enzyme prodrug therapy (ADEPT): a three phase systemS K Sharma, K D Bagshawe, C J Springer, et al.
Cell Biophysics|January 1, 1993
Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrugD C Blakey, B E Valcaccia, S East, et al.
Vaccine|February 14, 2016
Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulationMichael J Springer, Yawei Ni, Isaac Finger-Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinomaM P Napier, S K Sharma, C J Springer, et al.
Bioorganic & Medicinal Chemistry|February 5, 2013
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituentsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.
British Journal of Cancer|May 29, 2003
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugsR A Spooner, F Friedlos, K Maycroft, et al.
Oncogene|June 23, 2004
B-RAF is a therapeutic target in melanomaMaria Karasarides, Antonio Chiloeches, Robert Hayward, et al.
Pageof 28